[{"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. This question addresses a rare but catastrophic complication—tracheobronchial-gastric conduit fistula—occurring 18 days post-esophagectomy. Key discriminating findings: (1) early postoperative timing (18 days), (2) 5mm fistula at carina level, (3) sepsis and respiratory distress, (4) mediastinal contamination. The clinical scenario implies conduit ischemia at the anastomotic region, a known cause of such fistulas. Option B (emergency thoracotomy with fistula repair using muscle flap, conduit resection, and cervical esophagostomy) is the definitive surgical approach for early postoperative fistulas with contamination and likely conduit compromise. Option A (dual stenting) has high failure rates in early postoperative fistulas due to tissue friability and ongoing contamination. Option C (conservative management) is inadequate for a 5mm fistula with active sepsis. Option D (fibrin glue) is unsuitable for fistulas of this size. Option E (conduit abandonment without fistula repair) leaves the bronchial defect unrepaired, risking ongoing contamination. The keyed answer aligns with surgical literature on managing early postoperative conduit-airway fistulas. Medical accuracy: The management approach is consistent with specialized thoracic surgery guidelines. Minimal fix: None needed; item is logically sound and medically accurate.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. This question addresses a rare but catastrophic complication—tracheobronchial-gastric conduit fistula—occurring 18 days post-esophagectomy. Key discriminating findings: (1) early postoperative timing (18 days), (2) 5mm fistula at carina level, (3) sepsis and respiratory distress, (4) mediastinal contamination. The clinical scenario implies conduit ischemia at the anastomotic region, a known cause of such fistulas. Option B (emergency thoracotomy with fistula repair using muscle flap, conduit resection, and cervical esophagostomy) is the definitive surgical approach for early postoperative fistulas with contamination and likely conduit compromise. Option A (dual stenting) has high failure rates in early postoperative fistulas due to tissue friability and ongoing contamination. Option C (conservative management) is inadequate for a 5mm fistula with active sepsis. Option D (fibrin glue) is unsuitable for fistulas of this size. Option E (conduit abandonment without fistula repair) leaves the bronchial defect unrepaired, risking ongoing contamination. The keyed answer aligns with surgical literature on managing early postoperative conduit-airway fistulas. Medical accuracy: The management approach is consistent with specialized thoracic surgery guidelines. Minimal fix: None needed; item is logically sound and medically accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-002", "question": "A 54-year-old woman with antiphospholipid syndrome presents with 12 hours of severe epigastric pain and vomiting. CT angiography demonstrates thrombosis of the superior mesenteric vein extending into the intrahepatic portal veins, bowel wall thickening with pneumatosis of the proximal jejunum, and ascites. Exploratory laparotomy reveals dusky but viable small bowel without frank necrosis. What is the most appropriate next step?", "options": ["A) Resection of all affected bowel and mesenteric venous thrombectomy", "B) Systemic unfractionated heparin infusion targeting aPTT 2-3x control", "C) Catheter-directed thrombolysis of the superior mesenteric vein with alteplase via transhepatic approach", "D) Therapeutic enoxaparin 1 mg/kg twice daily and second-look laparotomy in 24 hours", "E) Mesenteric venous stent placement across the thrombosed segment"], "answer": "C", "answer_index": 2, "explanation": "In acute mesenteric venous thrombosis with bowel ischemia but viable intestine, catheter-directed thrombolysis restores venous outflow and prevents progression to infarction. Systemic anticoagulation alone is insufficient for extensive thrombus; surgical thrombectomy is ineffective and causes major bleeding.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer (C, catheter-directed thrombolysis) is not the most appropriate next step; the correct answer is D (anticoagulation + second-look laparotomy). Key stem clues: 54-year-old with antiphospholipid syndrome, acute mesenteric venous thrombosis with extensive involvement (SMV to intrahepatic portal veins), pneumatosis intestinalis (sign of transmural ischemia), and dusky but viable bowel at laparotomy. The critical finding is that laparotomy has already been performed and bowel is viable. Main logical issue: The question asks for the \\\"most appropriate next step\\\" after laparotomy reveals viable bowel. Standard management is immediate anticoagulation (heparin or enoxaparin) with planned second-look operation in 24-48 hours to reassess viability. Catheter-directed thrombolysis would have been considered pre-operatively or in stable patients without laparotomy, but once the abdomen is open with viable bowel, the priority is anticoagulation and close monitoring with second-look. The rationale incorrectly dismisses systemic anticoagulation as \\\"insufficient\\\" when it is actually first-line therapy for mesenteric venous thrombosis with viable bowel. Medical accuracy issue: The teaching point contradicts standard surgical management of acute MVT. Minimal fix: Change key to D or reframe the clinical scenario as pre-operative decision-making without laparotomy findings.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (C, catheter-directed thrombolysis) is not the most appropriate next step; the correct answer is D (anticoagulation + second-look laparotomy). Key stem clues: 54-year-old with antiphospholipid syndrome, acute mesenteric venous thrombosis with extensive involvement (SMV to intrahepatic portal veins), pneumatosis intestinalis (sign of transmural ischemia), and dusky but viable bowel at laparotomy. The critical finding is that laparotomy has already been performed and bowel is viable. Main logical issue: The question asks for the \"most appropriate next step\" after laparotomy reveals viable bowel. Standard management is immediate anticoagulation (heparin or enoxaparin) with planned second-look operation in 24-48 hours to reassess viability. Catheter-directed thrombolysis would have been considered pre-operatively or in stable patients without laparotomy, but once the abdomen is open with viable bowel, the priority is anticoagulation and close monitoring with second-look. The rationale incorrectly dismisses systemic anticoagulation as \"insufficient\" when it is actually first-line therapy for mesenteric venous thrombosis with viable bowel. Medical accuracy issue: The teaching point contradicts standard surgical management of acute MVT. Minimal fix: Change key to D or reframe the clinical scenario as pre-operative decision-making without laparotomy findings.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 42-year-old man with MEN1 syndrome presenting with a 2.8 cm duodenal gastrinoma with regional lymph node metastases. Key discriminating findings: (1) tumor size >2 cm indicating malignant potential, (2) confirmed lymph node metastases requiring oncologic resection, (3) MEN1 syndrome context where future pancreatic NETs are inevitable, (4) no current pancreatic lesions. The keyed answer (B) pancreas-preserving duodenectomy with lymphadenectomy is defensible as it achieves complete oncologic resection while preserving pancreatic parenchyma for future surgeries. Alternative analysis: (A) Whipple is overly morbid when pancreas is uninvolved and future pancreatic surgery is likely; (C) endoscopic resection inadequate for 2.8 cm tumor with nodal disease; (D) medical management alone inappropriate for resectable malignant disease with metastases; (E) enucleation fails to address documented lymph node metastases. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, consistent with specialized MEN1 management guidelines emphasizing pancreatic preservation. No significant medical errors identified. Minimal fix: none required; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 42-year-old man with MEN1 syndrome presenting with a 2.8 cm duodenal gastrinoma with regional lymph node metastases. Key discriminating findings: (1) tumor size >2 cm indicating malignant potential, (2) confirmed lymph node metastases requiring oncologic resection, (3) MEN1 syndrome context where future pancreatic NETs are inevitable, (4) no current pancreatic lesions. The keyed answer (B) pancreas-preserving duodenectomy with lymphadenectomy is defensible as it achieves complete oncologic resection while preserving pancreatic parenchyma for future surgeries. Alternative analysis: (A) Whipple is overly morbid when pancreas is uninvolved and future pancreatic surgery is likely; (C) endoscopic resection inadequate for 2.8 cm tumor with nodal disease; (D) medical management alone inappropriate for resectable malignant disease with metastases; (E) enucleation fails to address documented lymph node metastases. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, consistent with specialized MEN1 management guidelines emphasizing pancreatic preservation. No significant medical errors identified. Minimal fix: none required; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a classic presentation of hepatic sinusoidal obstruction syndrome (SOS/VOD) following oxaliplatin-based chemotherapy: painful hepatomegaly, ascites, jaundice, hyperbilirubinemia, elevated transaminases, coagulopathy, and pathognomonic histology (zone 3 sinusoidal congestion, hepatocyte necrosis, absence of portal inflammation). Key discriminating findings are the temporal relationship (3 weeks post-FOLFOX), characteristic triad of symptoms, and specific biopsy findings excluding other etiologies. Defibrotide (B) is the FDA-approved definitive therapy for severe SOS, acting via endothelial protection and fibrinolysis. Alternative analysis: (A) Steroids lack efficacy in SOS and may worsen outcomes. (C) TIPS is contraindicated in SOS due to diffuse sinusoidal injury rather than portal hypertension from cirrhosis. (D) N-acetylcysteine treats acetaminophen toxicity, not SOS. (E) Transplant is reserved for refractory cases with fulminant hepatic failure and encephalopathy, not first-line therapy. The item is medically accurate per current guidelines and logically sound with a unique best answer matching the key. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic presentation of hepatic sinusoidal obstruction syndrome (SOS/VOD) following oxaliplatin-based chemotherapy: painful hepatomegaly, ascites, jaundice, hyperbilirubinemia, elevated transaminases, coagulopathy, and pathognomonic histology (zone 3 sinusoidal congestion, hepatocyte necrosis, absence of portal inflammation). Key discriminating findings are the temporal relationship (3 weeks post-FOLFOX), characteristic triad of symptoms, and specific biopsy findings excluding other etiologies. Defibrotide (B) is the FDA-approved definitive therapy for severe SOS, acting via endothelial protection and fibrinolysis. Alternative analysis: (A) Steroids lack efficacy in SOS and may worsen outcomes. (C) TIPS is contraindicated in SOS due to diffuse sinusoidal injury rather than portal hypertension from cirrhosis. (D) N-acetylcysteine treats acetaminophen toxicity, not SOS. (E) Transplant is reserved for refractory cases with fulminant hepatic failure and encephalopathy, not first-line therapy. The item is medically accurate per current guidelines and logically sound with a unique best answer matching the key. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 35-year-old woman with CFH mutation (atypical HUS risk factor) who develops post-transplant TMA on day 7 despite prophylactic eculizumab. Key discriminating findings: (1) breakthrough TMA with rising creatinine, thrombocytopenia, schistocytes, hemolysis despite eculizumab prophylaxis; (2) platelets normalize but creatinine continues rising, suggesting incomplete complement blockade. The clinical problem is determining why eculizumab prophylaxis failed. Option D (measure trough level and CH50) is the correct next step because breakthrough TMA on eculizumab requires distinguishing pharmacokinetic failure (inadequate drug levels) from pharmacodynamic failure (incomplete complement blockade, C5 polymorphisms, or alternative pathway amplification). This guides rational therapy adjustment. Option A (empiric dose increase) is premature without knowing current drug levels. Option B (plasma exchange) is ineffective once eculizumab is started and doesn't address the underlying issue. Option C (switch to ravulizumab) doesn't solve the diagnostic uncertainty. Option E (nephrectomy) is premature without optimizing medical therapy. The item is logically valid with a unique best answer supported by standard TMA management principles. Medical accuracy is high, consistent with current atypical HUS guidelines emphasizing therapeutic drug monitoring for breakthrough events. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 35-year-old woman with CFH mutation (atypical HUS risk factor) who develops post-transplant TMA on day 7 despite prophylactic eculizumab. Key discriminating findings: (1) breakthrough TMA with rising creatinine, thrombocytopenia, schistocytes, hemolysis despite eculizumab prophylaxis; (2) platelets normalize but creatinine continues rising, suggesting incomplete complement blockade. The clinical problem is determining why eculizumab prophylaxis failed. Option D (measure trough level and CH50) is the correct next step because breakthrough TMA on eculizumab requires distinguishing pharmacokinetic failure (inadequate drug levels) from pharmacodynamic failure (incomplete complement blockade, C5 polymorphisms, or alternative pathway amplification). This guides rational therapy adjustment. Option A (empiric dose increase) is premature without knowing current drug levels. Option B (plasma exchange) is ineffective once eculizumab is started and doesn't address the underlying issue. Option C (switch to ravulizumab) doesn't solve the diagnostic uncertainty. Option E (nephrectomy) is premature without optimizing medical therapy. The item is logically valid with a unique best answer supported by standard TMA management principles. Medical accuracy is high, consistent with current atypical HUS guidelines emphasizing therapeutic drug monitoring for breakthrough events. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a post-allogeneic stem cell transplant patient presenting with hypertension, proteinuria, elevated LDH, hemolysis, and thrombocytopenia at day +45—classic features of transplant-associated thrombotic microangiopathy (TA-TMA). Key discriminating findings: (1) ADAMTS13 activity 45% (normal/near-normal, ruling out TTP), (2) tacrolimus recently stopped for rising creatinine (calcineurin inhibitor exposure is a known TA-TMA risk factor), (3) constellation of microangiopathic hemolytic anemia, thrombocytopenia, and renal injury post-transplant. TA-TMA is complement-mediated; eculizumab (terminal complement C5 inhibitor) is the evidence-based therapy and matches option A. Option B (steroids/plasma exchange) is appropriate for TTP but ineffective in TA-TMA with normal ADAMTS13. Option C (rituximab) lacks evidence for TA-TMA. Option D (resume tacrolimus) would worsen complement-mediated endothelial injury. Option E (supportive care only) is inadequate given high mortality without complement blockade. The keyed answer is medically accurate and uniquely defensible. No logical flaws or missing critical details. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a post-allogeneic stem cell transplant patient presenting with hypertension, proteinuria, elevated LDH, hemolysis, and thrombocytopenia at day +45—classic features of transplant-associated thrombotic microangiopathy (TA-TMA). Key discriminating findings: (1) ADAMTS13 activity 45% (normal/near-normal, ruling out TTP), (2) tacrolimus recently stopped for rising creatinine (calcineurin inhibitor exposure is a known TA-TMA risk factor), (3) constellation of microangiopathic hemolytic anemia, thrombocytopenia, and renal injury post-transplant. TA-TMA is complement-mediated; eculizumab (terminal complement C5 inhibitor) is the evidence-based therapy and matches option A. Option B (steroids/plasma exchange) is appropriate for TTP but ineffective in TA-TMA with normal ADAMTS13. Option C (rituximab) lacks evidence for TA-TMA. Option D (resume tacrolimus) would worsen complement-mediated endothelial injury. Option E (supportive care only) is inadequate given high mortality without complement blockade. The keyed answer is medically accurate and uniquely defensible. No logical flaws or missing critical details. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 14-year-old with confirmed CANDLE syndrome (PSMB8 mutation) refractory to dual IL-1 blockade (anakinra + canakinumab). Key discriminating findings: (1) confirmed proteasome-associated autoinflammatory syndrome (PSMB8 mutation), (2) failure of maximal IL-1 inhibition, (3) persistent inflammatory activity. CANDLE is a type I interferonopathy; proteasome dysfunction triggers constitutive interferon signaling. JAK inhibitors (baricitinib) block downstream interferon pathway signaling and have demonstrated efficacy in refractory CANDLE cases in published literature. The keyed answer (B, baricitinib) is the established next-line therapy. Alternative assessment: (A) High-dose steroids provide only temporary suppression with significant toxicity in chronic disease; (C) Tocilizumab (anti-IL-6) lacks efficacy in interferonopathies; (D) Thalidomide is not standard for CANDLE and has limited evidence; (E) Allogeneic transplant remains experimental/salvage therapy reserved for life-threatening refractory disease. No logical flaws: the clinical scenario uniquely points to JAK inhibition as the mechanistically appropriate next step after IL-1 blockade failure. Medical accuracy is high; aligns with current understanding of interferonopathy management. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 14-year-old with confirmed CANDLE syndrome (PSMB8 mutation) refractory to dual IL-1 blockade (anakinra + canakinumab). Key discriminating findings: (1) confirmed proteasome-associated autoinflammatory syndrome (PSMB8 mutation), (2) failure of maximal IL-1 inhibition, (3) persistent inflammatory activity. CANDLE is a type I interferonopathy; proteasome dysfunction triggers constitutive interferon signaling. JAK inhibitors (baricitinib) block downstream interferon pathway signaling and have demonstrated efficacy in refractory CANDLE cases in published literature. The keyed answer (B, baricitinib) is the established next-line therapy. Alternative assessment: (A) High-dose steroids provide only temporary suppression with significant toxicity in chronic disease; (C) Tocilizumab (anti-IL-6) lacks efficacy in interferonopathies; (D) Thalidomide is not standard for CANDLE and has limited evidence; (E) Allogeneic transplant remains experimental/salvage therapy reserved for life-threatening refractory disease. No logical flaws: the clinical scenario uniquely points to JAK inhibition as the mechanistically appropriate next step after IL-1 blockade failure. Medical accuracy is high; aligns with current understanding of interferonopathy management. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a patient from Vietnam (endemic area) with STAT1 gain-of-function mutation, disseminated umbilicated papular lesions, hepatosplenomegaly, fevers, and intracellular yeast with central septation on biopsy—classic for disseminated Talaromyces marneffei (formerly Penicillium marneffei). Key discriminating findings: (1) endemic geography, (2) STAT1 GOF causing defective Th17 immunity predisposing to dimorphic fungi, (3) pathognomonic histology showing intracellular yeast with central septation. Standard therapy for T. marneffei is liposomal amphotericin B induction followed by itraconazole maintenance. The critical addition is ruxolitinib (JAK1/2 inhibitor), which addresses the underlying STAT1 GOF immunodeficiency by reducing pathologic STAT1 hyperphosphorylation and restoring Th17 function—essential for cure in refractory cases. Option C uniquely combines all three components. Options A-B lack maintenance azole therapy and immunomodulation. Option D (echinocandin) has poor activity against dimorphic fungi. Option E (fluconazole) has inferior activity compared to itraconazole for T. marneffei. Medical accuracy: The item correctly identifies the pathogen, standard antifungal regimen, and emerging role of JAK inhibition in STAT1 GOF. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient from Vietnam (endemic area) with STAT1 gain-of-function mutation, disseminated umbilicated papular lesions, hepatosplenomegaly, fevers, and intracellular yeast with central septation on biopsy—classic for disseminated Talaromyces marneffei (formerly Penicillium marneffei). Key discriminating findings: (1) endemic geography, (2) STAT1 GOF causing defective Th17 immunity predisposing to dimorphic fungi, (3) pathognomonic histology showing intracellular yeast with central septation. Standard therapy for T. marneffei is liposomal amphotericin B induction followed by itraconazole maintenance. The critical addition is ruxolitinib (JAK1/2 inhibitor), which addresses the underlying STAT1 GOF immunodeficiency by reducing pathologic STAT1 hyperphosphorylation and restoring Th17 function—essential for cure in refractory cases. Option C uniquely combines all three components. Options A-B lack maintenance azole therapy and immunomodulation. Option D (echinocandin) has poor activity against dimorphic fungi. Option E (fluconazole) has inferior activity compared to itraconazole for T. marneffei. Medical accuracy: The item correctly identifies the pathogen, standard antifungal regimen, and emerging role of JAK inhibition in STAT1 GOF. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-009", "question": "A 65-year-old man with metastatic melanoma on ipilimumab 3 mg/kg plus nivolumab 1 mg/kg presents with severe fatigue, hypotension (BP 85/50 mmHg), hyponatremia (Na 122 mEq/L), and headache. Troponin I is 15 ng/mL with normal EF 55%. Brain MRI shows diffuse pituitary enlargement with homogeneous enhancement. What is immediate management?", "options": ["A) Methylprednisolone 1 mg/kg/day IV alone", "B) Methylprednisolone 1 mg/kg/day plus infliximab 5 mg/kg", "C) Methylprednisolone 1 mg/kg/day plus mycophenolate mofetil 1 g BID", "D) Methylprednisolone 1 g IV x3 days plus anti-thymocyte globulin", "E) Hold immunotherapy and initiate supportive care only"], "answer": "C", "answer_index": 2, "explanation": "Combined hypophysitis and myocarditis from dual checkpoint inhibition requires high-dose steroids. Mycophenolate mofetil is preferred for steroid-refractory myocarditis as infliximab can worsen myocardial inflammation. Anti-thymocyte globulin is overly immunosuppressive in this setting.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - option A is the correct best answer, not C. The vignette describes a patient with immune checkpoint inhibitor-induced hypophysitis (pituitary enlargement, hypotension, hyponatremia, fatigue) and myocarditis (elevated troponin). Key stem clues: dual checkpoint inhibition, severe hypotension/hyponatremia indicating adrenal crisis, troponin elevation with normal EF, pituitary enlargement. The immediate management priority is high-dose corticosteroids for both conditions. Option A (methylprednisolone 1 mg/kg/day IV) is appropriate initial therapy. The rationale incorrectly states mycophenolate is for 'steroid-refractory' myocarditis, but the patient hasn't received steroids yet - this is initial presentation, not refractory disease. Mycophenolate would be considered after steroid failure, not as immediate first-line therapy. Infliximab (option B) is contraindicated in ICI-myocarditis due to potential worsening. Options D and E are inappropriate (ATG too aggressive, supportive care alone inadequate). Medical accuracy issue: the keyed answer conflates initial management with refractory-disease management. Minimal fix: Change key to A, or modify stem to indicate 'steroid-refractory myocarditis after 3 days of methylprednisolone' to justify mycophenolate addition.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - option A is the correct best answer, not C. The vignette describes a patient with immune checkpoint inhibitor-induced hypophysitis (pituitary enlargement, hypotension, hyponatremia, fatigue) and myocarditis (elevated troponin). Key stem clues: dual checkpoint inhibition, severe hypotension/hyponatremia indicating adrenal crisis, troponin elevation with normal EF, pituitary enlargement. The immediate management priority is high-dose corticosteroids for both conditions. Option A (methylprednisolone 1 mg/kg/day IV) is appropriate initial therapy. The rationale incorrectly states mycophenolate is for 'steroid-refractory' myocarditis, but the patient hasn't received steroids yet - this is initial presentation, not refractory disease. Mycophenolate would be considered after steroid failure, not as immediate first-line therapy. Infliximab (option B) is contraindicated in ICI-myocarditis due to potential worsening. Options D and E are inappropriate (ATG too aggressive, supportive care alone inadequate). Medical accuracy issue: the keyed answer conflates initial management with refractory-disease management. Minimal fix: Change key to A, or modify stem to indicate 'steroid-refractory myocarditis after 3 days of methylprednisolone' to justify mycophenolate addition.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a patient with hereditary alpha-tryptasemia (HαT) syndrome—confirmed by TPSAB1 copy number gain and elevated baseline tryptase (35 ng/mL)—presenting with refractory mast cell activation symptoms despite optimized antihistamine therapy (high-dose cetirizine) and omalizumab. Key discriminating findings: (1) genetic confirmation of HαT, (2) failure of standard therapies, (3) chronic urticaria and anaphylaxis consistent with mast cell mediator release. The keyed answer (D, ketotifen) is defensible as a mast cell stabilizer with systemic absorption and documented efficacy in refractory mast cell activation disorders when antihistamines fail. Alternative assessments: (A) Increasing omalizumab lacks strong evidence in HαT and the patient already failed standard dosing; (B) chronic corticosteroids carry unacceptable toxicity for prophylaxis; (C) cromolyn has poor systemic bioavailability (~1%) limiting efficacy for systemic symptoms; (E) allergen immunotherapy is inappropriate without identified allergen triggers in idiopathic anaphylaxis. The item is logically valid with one defensible best answer. Medical accuracy is high, consistent with current understanding of HαT management. Minimal fix: None required; item is sound.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient with hereditary alpha-tryptasemia (HαT) syndrome—confirmed by TPSAB1 copy number gain and elevated baseline tryptase (35 ng/mL)—presenting with refractory mast cell activation symptoms despite optimized antihistamine therapy (high-dose cetirizine) and omalizumab. Key discriminating findings: (1) genetic confirmation of HαT, (2) failure of standard therapies, (3) chronic urticaria and anaphylaxis consistent with mast cell mediator release. The keyed answer (D, ketotifen) is defensible as a mast cell stabilizer with systemic absorption and documented efficacy in refractory mast cell activation disorders when antihistamines fail. Alternative assessments: (A) Increasing omalizumab lacks strong evidence in HαT and the patient already failed standard dosing; (B) chronic corticosteroids carry unacceptable toxicity for prophylaxis; (C) cromolyn has poor systemic bioavailability (~1%) limiting efficacy for systemic symptoms; (E) allergen immunotherapy is inappropriate without identified allergen triggers in idiopathic anaphylaxis. The item is logically valid with one defensible best answer. Medical accuracy is high, consistent with current understanding of HαT management. Minimal fix: None required; item is sound.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-011", "question": "A 57-year-old man is 6 hours status post bilateral sequential lung transplantation for idiopathic pulmonary fibrosis. He remains on 100% FiO2 with PaO2/FiO2 ratio of 85 despite inhaled nitric oxide at 40 ppm and optimal ventilator settings. Chest X-ray shows diffuse bilateral infiltrates. What is the optimal mechanical support strategy?", "options": ["A) Veno-venous ECMO via femoral-jugular cannulation", "B) Veno-arterial ECMO via central cannulation", "C) Extracorporeal CO2 removal with 1 L/min blood flow", "D) Inhaled epoprostenol 50 ng/kg/min only", "E) Veno-venous ECMO via dual-lumen cannula (Avalon) in right internal jugular vein"], "answer": "E", "answer_index": 4, "explanation": "Severe primary graft dysfunction grade 3 requires full respiratory support. Dual-lumen single-site VV-ECMO (Avalon) allows early mobilization and rehabilitation, which improves long-term outcomes. Femoral-jugular configuration limits mobility; VA-ECMO is unnecessary without cardiac failure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best. The vignette describes severe primary graft dysfunction (PGD) grade 3 post-lung transplant: PaO2/FiO2 ratio 85 (severe ARDS criteria <100), refractory hypoxemia despite maximal medical therapy (100% FiO2, inhaled NO 40 ppm), and bilateral infiltrates at 6 hours post-op. Key discriminators: (1) isolated severe respiratory failure without stated cardiac dysfunction, (2) post-transplant patient requiring prolonged support with rehabilitation needs. Option E (dual-lumen VV-ECMO via Avalon catheter) is the unique best answer: provides full respiratory support for severe hypoxemia while preserving mobility for early ambulation—critical in transplant patients to prevent deconditioning and improve graft outcomes. Option A (femoral-jugular VV-ECMO) provides equivalent gas exchange but immobilizes the patient, hindering rehabilitation. Option B (VA-ECMO) is unnecessary without cardiac failure and adds arterial complications. Option C (ECCO2R at 1 L/min) provides inadequate oxygenation for PaO2/FiO2 of 85. Option D (inhaled epoprostenol alone) is insufficient given failure of inhaled NO. The item correctly identifies Avalon as superior for this specific post-transplant context. Medical accuracy: consistent with transplant ECMO guidelines emphasizing early mobilization. No logical flaws; single defensible best answer matching the key. Minimal fix: none needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best. The vignette describes severe primary graft dysfunction (PGD) grade 3 post-lung transplant: PaO2/FiO2 ratio 85 (severe ARDS criteria <100), refractory hypoxemia despite maximal medical therapy (100% FiO2, inhaled NO 40 ppm), and bilateral infiltrates at 6 hours post-op. Key discriminators: (1) isolated severe respiratory failure without stated cardiac dysfunction, (2) post-transplant patient requiring prolonged support with rehabilitation needs. Option E (dual-lumen VV-ECMO via Avalon catheter) is the unique best answer: provides full respiratory support for severe hypoxemia while preserving mobility for early ambulation—critical in transplant patients to prevent deconditioning and improve graft outcomes. Option A (femoral-jugular VV-ECMO) provides equivalent gas exchange but immobilizes the patient, hindering rehabilitation. Option B (VA-ECMO) is unnecessary without cardiac failure and adds arterial complications. Option C (ECCO2R at 1 L/min) provides inadequate oxygenation for PaO2/FiO2 of 85. Option D (inhaled epoprostenol alone) is insufficient given failure of inhaled NO. The item correctly identifies Avalon as superior for this specific post-transplant context. Medical accuracy: consistent with transplant ECMO guidelines emphasizing early mobilization. No logical flaws; single defensible best answer matching the key. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 5.5 cm inflammatory AAA with periaortic inflammation, bilateral ureteral obstruction, and elevated inflammatory markers. Key discriminating findings: aneurysm size at surgical threshold (5.5 cm), inflammatory rind, ureteral obstruction, elevated ESR/CRP. The clinical problem asks for optimal management sequence. Option D (steroids then EVAR) is keyed as correct. However, Option B (EVAR then steroids) is equally defensible. In inflammatory AAA, both approaches are used: some advocate initial steroids to reduce inflammation before repair, while others prioritize definitive aneurysm repair (especially at 5.5 cm threshold) followed by steroids for residual inflammation. The stem does not specify rupture risk, hemodynamic instability, or degree of ureteral compromise that would favor one sequence over another. Both EVAR-first and steroids-first strategies have literature support. The distinction between 40 mg daily versus 1 mg/kg (~70 mg for this patient) further complicates comparison but doesn't resolve the sequencing ambiguity. Medical accuracy: The keyed answer reflects one valid approach, but the item fails to provide discriminating details that make it uniquely superior to Option B. Minimal fix: Add clinical details favoring delayed repair (e.g., stable aneurysm, severe inflammation precluding immediate EVAR, or successful ureteral stenting).\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 5.5 cm inflammatory AAA with periaortic inflammation, bilateral ureteral obstruction, and elevated inflammatory markers. Key discriminating findings: aneurysm size at surgical threshold (5.5 cm), inflammatory rind, ureteral obstruction, elevated ESR/CRP. The clinical problem asks for optimal management sequence. Option D (steroids then EVAR) is keyed as correct. However, Option B (EVAR then steroids) is equally defensible. In inflammatory AAA, both approaches are used: some advocate initial steroids to reduce inflammation before repair, while others prioritize definitive aneurysm repair (especially at 5.5 cm threshold) followed by steroids for residual inflammation. The stem does not specify rupture risk, hemodynamic instability, or degree of ureteral compromise that would favor one sequence over another. Both EVAR-first and steroids-first strategies have literature support. The distinction between 40 mg daily versus 1 mg/kg (~70 mg for this patient) further complicates comparison but doesn't resolve the sequencing ambiguity. Medical accuracy: The keyed answer reflects one valid approach, but the item fails to provide discriminating details that make it uniquely superior to Option B. Minimal fix: Add clinical details favoring delayed repair (e.g., stable aneurysm, severe inflammation precluding immediate EVAR, or successful ureteral stenting).", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-013", "question": "A 58-year-old woman presents with a 4 cm pancreatic tail tumor, necrolytic migratory erythema, weight loss of 30 lbs, and new-onset diabetes. Biopsy confirms glucagonoma with Ki-67 8% and diffuse hepatic metastases on MRI. Serum glucagon is 2,500 pg/mL. What is first-line therapy?", "options": ["A) Distal pancreatectomy with splenectomy", "B) Octreotide LAR 30 mg intramuscular monthly", "C) Lanreotide autogel 120 mg deep subcutaneous every 4 weeks", "D) Everolimus 10 mg daily plus octreotide LAR", "E) Streptozocin 500 mg/m2 plus doxorubicin 50 mg/m2 every 3 weeks"], "answer": "C", "answer_index": 2, "explanation": "For metastatic glucagonoma, long-acting somatostatin analogs control hormone symptoms and have antiproliferative activity. Lanreotide 120 mg every 4 weeks is preferred over octreotide LAR due to consistent dosing. Everolimus is second-line; chemotherapy is reserved for progressive disease.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a metastatic glucagonoma (Ki-67 8%, diffuse hepatic metastases) with classic syndrome features. Key stem clues: metastatic disease, low-intermediate Ki-67, symptomatic hormone excess. The question asks for \\\"first-line therapy.\\\" Both options B (octreotide LAR 30 mg monthly) and C (lanreotide 120 mg every 4 weeks) are long-acting somatostatin analogs with equivalent efficacy for symptom control and antiproliferative effects in metastatic neuroendocrine tumors. The rationale claims lanreotide is \\\"preferred...due to consistent dosing,\\\" but this is not a medically established superiority criterion—both agents have comparable efficacy and are guideline-recommended first-line options. No stem detail (patient preference, prior treatment, formulary) differentiates them. Option D (everolimus plus octreotide) represents combination therapy typically reserved for progressive disease after SSA monotherapy. The item creates an artificial distinction between two therapeutically equivalent first-line agents without providing discriminating information. Minimal fix: Reframe the question to ask about the mechanism of first-line therapy (allowing either SSA as correct) or specify a clinical factor (e.g., patient preference for injection frequency, prior octreotide failure) that would justify selecting one SSA over the other.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a metastatic glucagonoma (Ki-67 8%, diffuse hepatic metastases) with classic syndrome features. Key stem clues: metastatic disease, low-intermediate Ki-67, symptomatic hormone excess. The question asks for \"first-line therapy.\" Both options B (octreotide LAR 30 mg monthly) and C (lanreotide 120 mg every 4 weeks) are long-acting somatostatin analogs with equivalent efficacy for symptom control and antiproliferative effects in metastatic neuroendocrine tumors. The rationale claims lanreotide is \"preferred...due to consistent dosing,\" but this is not a medically established superiority criterion—both agents have comparable efficacy and are guideline-recommended first-line options. No stem detail (patient preference, prior treatment, formulary) differentiates them. Option D (everolimus plus octreotide) represents combination therapy typically reserved for progressive disease after SSA monotherapy. The item creates an artificial distinction between two therapeutically equivalent first-line agents without providing discriminating information. Minimal fix: Reframe the question to ask about the mechanism of first-line therapy (allowing either SSA as correct) or specify a clinical factor (e.g., patient preference for injection frequency, prior octreotide failure) that would justify selecting one SSA over the other.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-014", "question": "A 35-year-old woman has chronic iron deficiency anemia requiring IV iron every 3 months, recurrent episodes of partial small bowel obstruction, and capsule endoscopy shows 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. What is the diagnosis and treatment?", "options": ["A) Crohn's disease: start infliximab", "B) NSAID enteropathy: stop all NSAIDs", "C) Cryptogenic multifocal ulcerous stenosing enteritis: budesonide 9 mg daily", "D) Small bowel lymphoma: R-CHOP chemotherapy", "E) Refractory celiac disease: cladribine"], "answer": "C", "answer_index": 2, "explanation": "Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is characterized by multiple short ulcerated strictures without transmural inflammation. Diagnosis requires exclusion of Crohn's disease and NSAID injury. Budesonide induces remission; anti-TNF agents are ineffective. Capsule retention risk requires patency assessment.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 35-year-old woman with chronic iron deficiency anemia, recurrent partial small bowel obstruction, and 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. Key discriminating findings: multiple short strictures, superficial ulceration, absence of granulomas (argues against Crohn's), absence of crypt distortion (argues against celiac). The stem lacks critical information: (1) NSAID use history is not stated—essential to exclude NSAID enteropathy (option B), which is far more common than CMUSE and presents identically; (2) serologic testing for celiac disease is not mentioned; (3) no statement about excluding Crohn's disease through imaging or other means. CMUSE is an extremely rare diagnosis of exclusion requiring explicit ruling out of NSAIDs and Crohn's. Without knowing NSAID exposure status, both B and C remain defensible. The item assumes NSAID use was excluded without stating it. Medical accuracy: CMUSE description and budesonide treatment are accurate for this rare entity, but the diagnostic workup is incomplete. Minimal fix: Add 'denies NSAID use' and 'negative celiac serology' to the stem to make C uniquely defensible.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 35-year-old woman with chronic iron deficiency anemia, recurrent partial small bowel obstruction, and 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. Key discriminating findings: multiple short strictures, superficial ulceration, absence of granulomas (argues against Crohn's), absence of crypt distortion (argues against celiac). The stem lacks critical information: (1) NSAID use history is not stated—essential to exclude NSAID enteropathy (option B), which is far more common than CMUSE and presents identically; (2) serologic testing for celiac disease is not mentioned; (3) no statement about excluding Crohn's disease through imaging or other means. CMUSE is an extremely rare diagnosis of exclusion requiring explicit ruling out of NSAIDs and Crohn's. Without knowing NSAID exposure status, both B and C remain defensible. The item assumes NSAID use was excluded without stating it. Medical accuracy: CMUSE description and budesonide treatment are accurate for this rare entity, but the diagnostic workup is incomplete. Minimal fix: Add 'denies NSAID use' and 'negative celiac serology' to the stem to make C uniquely defensible.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-015", "question": "A 45-year-old HIV-positive man on tenofovir DF/emtricitabine for 10 years presents with proximal muscle weakness, bone pain, and hypophosphatemia of 1.8 mg/dL. Urine studies show phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. What is the optimal electrolyte replacement regimen?", "options": ["A) Oral sodium phosphate 1 g TID alone", "B) Oral sodium phosphate plus calcitriol 0.25 mcg daily", "C) IV sodium phosphate 0.16 mmol/kg bolus then oral phosphate", "D) Oral sodium phosphate plus sodium bicarbonate 650 mg TID", "E) Stop tenofovir only"], "answer": "D", "answer_index": 3, "explanation": "Tenofovir-induced Fanconi syndrome causes proximal tubular loss of phosphate, glucose, and bicarbonate. Replacement requires both phosphate and bicarbonate to correct metabolic acidosis and prevent osteomalacia. Calcitriol is unnecessary if 25-OH vitamin D is normal; stopping tenofovir is necessary but insufficient for severe deficiency.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes tenofovir-induced Fanconi syndrome (proximal renal tubular acidosis type 2) with classic triad: hypophosphatemia (1.8 mg/dL, normal 2.5-4.5), phosphaturia, glucosuria with normoglycemia, plus metabolic acidosis and proximal muscle weakness/bone pain suggesting osteomalacia. Key discriminating findings: 10-year tenofovir exposure, severe hypophosphatemia, metabolic acidosis requiring dual correction. Option D (oral phosphate + bicarbonate) addresses both deficits appropriately. Option A replaces only phosphate, ignoring acidosis. Option B adds calcitriol unnecessarily when 1,25-vitamin D production is typically preserved in isolated Fanconi; calcitriol risks hypercalcemia without addressing acidosis. Option C uses IV phosphate inappropriately (reserved for severe symptomatic hypophosphatemia <1 mg/dL with cardiac/respiratory compromise). Option E (stop tenofovir only) is necessary long-term but insufficient acutely for severe electrolyte derangements requiring active replacement. The item correctly identifies that optimal management requires addressing both the phosphate deficit and metabolic acidosis simultaneously. Medical accuracy is sound: tenofovir nephrotoxicity is well-established, and dual replacement is standard. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes tenofovir-induced Fanconi syndrome (proximal renal tubular acidosis type 2) with classic triad: hypophosphatemia (1.8 mg/dL, normal 2.5-4.5), phosphaturia, glucosuria with normoglycemia, plus metabolic acidosis and proximal muscle weakness/bone pain suggesting osteomalacia. Key discriminating findings: 10-year tenofovir exposure, severe hypophosphatemia, metabolic acidosis requiring dual correction. Option D (oral phosphate + bicarbonate) addresses both deficits appropriately. Option A replaces only phosphate, ignoring acidosis. Option B adds calcitriol unnecessarily when 1,25-vitamin D production is typically preserved in isolated Fanconi; calcitriol risks hypercalcemia without addressing acidosis. Option C uses IV phosphate inappropriately (reserved for severe symptomatic hypophosphatemia <1 mg/dL with cardiac/respiratory compromise). Option E (stop tenofovir only) is necessary long-term but insufficient acutely for severe electrolyte derangements requiring active replacement. The item correctly identifies that optimal management requires addressing both the phosphate deficit and metabolic acidosis simultaneously. Medical accuracy is sound: tenofovir nephrotoxicity is well-established, and dual replacement is standard. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-016", "question": "A 70-year-old man with coronary artery disease is found to have clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation at variant allele frequency of 12% on peripheral blood NGS. CBC is normal and there is no splenomegaly. What is his annual risk of thrombosis and recommended prophylaxis?", "options": ["A) 1% annual thrombosis risk; no prophylaxis needed", "B) 5% annual thrombosis risk; start hydroxyurea", "C) 0.5% annual thrombosis risk; start low-dose aspirin", "D) 10% annual thrombosis risk; start therapeutic enoxaparin", "E) No increased thrombosis risk; no prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "CHIP with JAK2 V617F confers a 0.5-1% annual risk of thrombosis independent of traditional risk factors. Low-dose aspirin is recommended for primary prophylaxis. Progression to myelofibrosis or AML is rare (<1% annually). Hydroxyurea is not indicated without overt myeloproliferative neoplasm.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes CHIP with JAK2 V617F (VAF 12%) in a patient with CAD, normal CBC, no splenomegaly. The question asks for annual thrombosis risk AND recommended prophylaxis. Key stem clues: JAK2 V617F CHIP, CAD (cardiovascular risk factor), normal CBC (excludes overt MPN). The keyed answer (C) states 0.5% risk with aspirin prophylaxis. However, option A (1% risk, no prophylaxis) is equally defensible because: (1) published data show CHIP-JAK2 thrombosis risk ranges 0.5-2% annually depending on VAF and comorbidities; (2) aspirin prophylaxis for CHIP-JAK2 is not universally recommended in guidelines—most sources suggest managing traditional cardiovascular risk factors without CHIP-specific antiplatelet therapy unless overt MPN develops. The rationale cites 0.5-1% risk and recommends aspirin, but this represents expert opinion rather than consensus guideline. Medical accuracy issue: The aspirin recommendation for CHIP (without overt MPN) lacks strong evidence-based support; current practice typically reserves cytoreduction/antiplatelet therapy for diagnosed MPNs. The item conflates CHIP management with MPN management. Minimal fix: Specify whether aspirin is recommended specifically for CHIP-JAK2 or for the patient's underlying CAD, or reframe to ask only about thrombosis risk without prophylaxis recommendation.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes CHIP with JAK2 V617F (VAF 12%) in a patient with CAD, normal CBC, no splenomegaly. The question asks for annual thrombosis risk AND recommended prophylaxis. Key stem clues: JAK2 V617F CHIP, CAD (cardiovascular risk factor), normal CBC (excludes overt MPN). The keyed answer (C) states 0.5% risk with aspirin prophylaxis. However, option A (1% risk, no prophylaxis) is equally defensible because: (1) published data show CHIP-JAK2 thrombosis risk ranges 0.5-2% annually depending on VAF and comorbidities; (2) aspirin prophylaxis for CHIP-JAK2 is not universally recommended in guidelines—most sources suggest managing traditional cardiovascular risk factors without CHIP-specific antiplatelet therapy unless overt MPN develops. The rationale cites 0.5-1% risk and recommends aspirin, but this represents expert opinion rather than consensus guideline. Medical accuracy issue: The aspirin recommendation for CHIP (without overt MPN) lacks strong evidence-based support; current practice typically reserves cytoreduction/antiplatelet therapy for diagnosed MPNs. The item conflates CHIP management with MPN management. Minimal fix: Specify whether aspirin is recommended specifically for CHIP-JAK2 or for the patient's underlying CAD, or reframe to ask only about thrombosis risk without prophylaxis recommendation.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-017", "question": "A 22-year-old man has recurrent sinopulmonary infections with Streptococcus pneumoniae, systemic lupus erythematosus-like malar rash, and low C1q level of 5 mg/dL (normal 10-25) with normal C1r and C1s. Genetic testing shows homozygous C1QA c.150C>G mutation. What is the recommended infection prophylaxis?", "options": ["A) Penicillin V 250 mg BID lifelong", "B) IVIG 400 mg/kg monthly", "C) No prophylaxis needed", "D) Posaconazole 300 mg daily", "E) Pneumococcal vaccine only"], "answer": "A", "answer_index": 0, "explanation": "C1q deficiency causes impaired classical pathway opsonization of encapsulated organisms and SLE-like autoimmunity. Lifelong penicillin prophylaxis is recommended to prevent invasive pneumococcal disease. IVIG is not indicated unless specific antibody deficiency coexists; fungal prophylaxis is unnecessary.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem describes C1q deficiency with recurrent S. pneumoniae infections and SLE-like features. Key discriminating findings: homozygous C1QA mutation, low C1q (5 mg/dL), recurrent sinopulmonary infections with S. pneumoniae, normal C1r/C1s. The question asks for recommended infection prophylaxis. The keyed answer (A: Penicillin V 250 mg BID lifelong) assumes antibiotic prophylaxis is standard for C1q deficiency. However, C1q deficiency management is not well-standardized in major guidelines. While prophylactic antibiotics are used for asplenia and certain antibody deficiencies, C1q deficiency primarily causes SLE-like autoimmunity; infection susceptibility varies. Option B (IVIG) could be defensible if antibody production is impaired (complement deficiencies can coexist with antibody defects). Option E (vaccine only) represents a conservative approach used in many complement deficiencies. The stem lacks critical information: (1) antibody levels/vaccine responses, (2) infection severity/frequency justifying lifelong antibiotics, (3) institutional protocol. Without established guidelines specifically mandating lifelong penicillin for C1q deficiency, multiple approaches (A, B, or E) could be defended. Minimal fix: Add \\\"patient has failed pneumococcal vaccination with poor antibody response\\\" or cite specific guideline recommending lifelong penicillin for C1q deficiency.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The stem describes C1q deficiency with recurrent S. pneumoniae infections and SLE-like features. Key discriminating findings: homozygous C1QA mutation, low C1q (5 mg/dL), recurrent sinopulmonary infections with S. pneumoniae, normal C1r/C1s. The question asks for recommended infection prophylaxis. The keyed answer (A: Penicillin V 250 mg BID lifelong) assumes antibiotic prophylaxis is standard for C1q deficiency. However, C1q deficiency management is not well-standardized in major guidelines. While prophylactic antibiotics are used for asplenia and certain antibody deficiencies, C1q deficiency primarily causes SLE-like autoimmunity; infection susceptibility varies. Option B (IVIG) could be defensible if antibody production is impaired (complement deficiencies can coexist with antibody defects). Option E (vaccine only) represents a conservative approach used in many complement deficiencies. The stem lacks critical information: (1) antibody levels/vaccine responses, (2) infection severity/frequency justifying lifelong antibiotics, (3) institutional protocol. Without established guidelines specifically mandating lifelong penicillin for C1q deficiency, multiple approaches (A, B, or E) could be defended. Minimal fix: Add \"patient has failed pneumococcal vaccination with poor antibody response\" or cite specific guideline recommending lifelong penicillin for C1q deficiency.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-018", "question": "A 68-year-old man on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL) develops a cavitary right upper lobe lung lesion. Biopsy shows broad nonseptate hyphae with right-angle branching. What is the optimal antifungal combination therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone", "B) Amphotericin B plus posaconazole 300 mg daily", "C) Isavuconazole 372 mg daily", "D) Amphotericin B plus deferasirox 20 mg/kg daily", "E) Caspofungin 50 mg daily plus posaconazole"], "answer": "D", "answer_index": 3, "explanation": "Deferoxamine is a siderophore that enhances mucoraceal growth and must be stopped. Deferasirox has intrinsic antifungal activity against Mucorales. Liposomal amphotericin B is first-line; combination with deferasirox improves outcomes. Isavuconazole is second-line monotherapy; caspofungin has minimal activity.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. Key stem clues: 68-year-old on deferoxamine with cavitary lung lesion showing broad nonseptate hyphae with right-angle branching (classic mucormycosis). The question asks for 'optimal antifungal combination therapy.' Critical issue: Option D (Amphotericin B plus deferasirox) is problematic because deferasirox is an iron chelator, not an antifungal agent. While deferasirox has in-vitro activity against Mucorales and should replace deferoxamine (which promotes fungal growth), it is NOT standard antifungal combination therapy. The optimal answer should be B (Amphotericin B plus posaconazole), which represents true antifungal combination therapy per current guidelines. Liposomal amphotericin B is first-line for mucormycosis; posaconazole is the recommended azole for combination or salvage therapy. Option D conflates iron chelator management (stopping deferoxamine, switching to deferasirox) with antifungal therapy. Medical accuracy issue: Deferasirox is not classified as antifungal combination therapy in standard guidelines. Minimal fix: Change key to B, or reword question to ask about 'optimal management strategy including iron chelation' to justify option D.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best answer. Key stem clues: 68-year-old on deferoxamine with cavitary lung lesion showing broad nonseptate hyphae with right-angle branching (classic mucormycosis). The question asks for 'optimal antifungal combination therapy.' Critical issue: Option D (Amphotericin B plus deferasirox) is problematic because deferasirox is an iron chelator, not an antifungal agent. While deferasirox has in-vitro activity against Mucorales and should replace deferoxamine (which promotes fungal growth), it is NOT standard antifungal combination therapy. The optimal answer should be B (Amphotericin B plus posaconazole), which represents true antifungal combination therapy per current guidelines. Liposomal amphotericin B is first-line for mucormycosis; posaconazole is the recommended azole for combination or salvage therapy. Option D conflates iron chelator management (stopping deferoxamine, switching to deferasirox) with antifungal therapy. Medical accuracy issue: Deferasirox is not classified as antifungal combination therapy in standard guidelines. Minimal fix: Change key to B, or reword question to ask about 'optimal management strategy including iron chelation' to justify option D.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-019", "question": "A 62-year-old woman with high-grade serous ovarian cancer develops subacute cerebellar ataxia, dysarthria, and nystagmus over 3 weeks. Anti-Yo antibodies are positive at titer 1:10,240 in serum and CSF. CSF shows lymphocytic pleocytosis (50 cells/μL). What is the immunotherapy protocol?", "options": ["A) Methylprednisolone 1 g IV x3 days then prednisone 1 mg/kg", "B) IVIG 2 g/kg monthly", "C) Cyclophosphamide 750 mg/m2 monthly plus prednisone", "D) Rituximab 375 mg/m2 weekly x4 plus prednisone", "E) Tumor debulking surgery only"], "answer": "C", "answer_index": 2, "explanation": "Anti-Yo associated paraneoplastic cerebellar degeneration is B-cell mediated; cyclophosphamide crosses the blood-brain barrier and depletes plasma cells more effectively than rituximab. Combined with steroids, it stabilizes neurologic decline. IVIG is less effective for anti-Yo; tumor treatment alone is insufficient.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the provided key does not match current standard management. The stem describes classic anti-Yo paraneoplastic cerebellar degeneration (PCD) in ovarian cancer with subacute cerebellar syndrome, high-titer anti-Yo antibodies, and CSF inflammation. Key discriminating findings: high-grade serous ovarian cancer, anti-Yo positivity, cerebellar syndrome. The question asks for \\\"immunotherapy protocol.\\\" The keyed answer (C: cyclophosphamide+prednisone) reflects older literature suggesting aggressive immunosuppression. However, current consensus (Graus 2021 guidelines, UpToDate) establishes that anti-Yo PCD responds poorly to immunotherapy; the primary intervention is tumor treatment (surgery/chemotherapy). Option E (tumor debulking surgery) is the evidence-based best answer. While steroids (A) may provide modest symptomatic benefit, aggressive immunosuppression (C, D) lacks efficacy data and is not standard. The rationale's claim that cyclophosphamide \\\"stabilizes neurologic decline\\\" is not supported by current evidence - anti-Yo PCD typically progresses despite immunotherapy. Main logical issue: the key contradicts established management guidelines. Main medical accuracy issue: the rationale promotes ineffective immunosuppression over definitive tumor treatment. Minimal fix: Change key to E and revise rationale to state tumor treatment is primary; immunotherapy has limited benefit in anti-Yo PCD.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the provided key does not match current standard management. The stem describes classic anti-Yo paraneoplastic cerebellar degeneration (PCD) in ovarian cancer with subacute cerebellar syndrome, high-titer anti-Yo antibodies, and CSF inflammation. Key discriminating findings: high-grade serous ovarian cancer, anti-Yo positivity, cerebellar syndrome. The question asks for \"immunotherapy protocol.\" The keyed answer (C: cyclophosphamide+prednisone) reflects older literature suggesting aggressive immunosuppression. However, current consensus (Graus 2021 guidelines, UpToDate) establishes that anti-Yo PCD responds poorly to immunotherapy; the primary intervention is tumor treatment (surgery/chemotherapy). Option E (tumor debulking surgery) is the evidence-based best answer. While steroids (A) may provide modest symptomatic benefit, aggressive immunosuppression (C, D) lacks efficacy data and is not standard. The rationale's claim that cyclophosphamide \"stabilizes neurologic decline\" is not supported by current evidence - anti-Yo PCD typically progresses despite immunotherapy. Main logical issue: the key contradicts established management guidelines. Main medical accuracy issue: the rationale promotes ineffective immunosuppression over definitive tumor treatment. Minimal fix: Change key to E and revise rationale to state tumor treatment is primary; immunotherapy has limited benefit in anti-Yo PCD.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-020", "question": "A 35-year-old man develops fever, facial edema, diffuse erythematous rash covering 60% BSA, eosinophilia of 2,200/μL, and atypical lymphocytes 3 weeks after starting allopurinol 300 mg daily for gout. AST is 850 U/L and ALT is 620 U/L. What is the appropriate corticosteroid regimen?", "options": ["A) Prednisone 1 mg/kg PO daily, taper over 2 weeks", "B) Methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks", "C) Methylprednisolone 1 g IV x3 days only", "D) No steroids; antihistamines and topical therapy", "E) Topical triamcinolone 0.1% BSA"], "answer": "B", "answer_index": 1, "explanation": "DRESS syndrome with hepatitis requires high-dose systemic steroids; rapid taper risks relapse and rebound hepatitis. Slow taper over 8-12 weeks with monitoring for viral reactivation (HHV-6) is standard. Pulse therapy alone is insufficient; antihistamines are adjunctive only.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms): fever, facial edema, extensive rash (>60% BSA), eosinophilia >1,500/μL, atypical lymphocytes, and hepatitis (AST/ALT elevation) occurring 2-4 weeks after allopurinol initiation—a well-known culprit. The question asks for appropriate corticosteroid management. Key discriminators: severe systemic involvement (60% BSA, hepatitis with AST 850, ALT 620) mandates systemic corticosteroids; DRESS characteristically requires prolonged taper (8-12 weeks) because rapid withdrawal causes flares and rebound hepatitis. Option B (methylprednisolone 1-2 mg/kg IV, slow 8-12 week taper) matches standard DRESS management guidelines. Option A (2-week taper) is too short and risks relapse. Option C (pulse therapy alone) lacks maintenance phase. Option D (no steroids) is inadequate for severe DRESS with hepatitis. Option E (topical only) is insufficient for systemic disease. The keyed answer aligns with current consensus on DRESS treatment requiring prolonged systemic corticosteroid therapy. No logical flaws or medical inaccuracies identified. Minimal fix: none needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms): fever, facial edema, extensive rash (>60% BSA), eosinophilia >1,500/μL, atypical lymphocytes, and hepatitis (AST/ALT elevation) occurring 2-4 weeks after allopurinol initiation—a well-known culprit. The question asks for appropriate corticosteroid management. Key discriminators: severe systemic involvement (60% BSA, hepatitis with AST 850, ALT 620) mandates systemic corticosteroids; DRESS characteristically requires prolonged taper (8-12 weeks) because rapid withdrawal causes flares and rebound hepatitis. Option B (methylprednisolone 1-2 mg/kg IV, slow 8-12 week taper) matches standard DRESS management guidelines. Option A (2-week taper) is too short and risks relapse. Option C (pulse therapy alone) lacks maintenance phase. Option D (no steroids) is inadequate for severe DRESS with hepatitis. Option E (topical only) is insufficient for systemic disease. The keyed answer aligns with current consensus on DRESS treatment requiring prolonged systemic corticosteroid therapy. No logical flaws or medical inaccuracies identified. Minimal fix: none needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]